- Home
- EXEL vs PSO Comparison
EXEL vs PSO Comparison
Compare EXEL & PSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- PSO
- Stock Information
- Founded
- EXEL 1994
- PSO 1844
- Country
- EXEL United States
- PSO United Kingdom
- Employees
- EXEL N/A
- PSO N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- PSO Books
- Sector
- EXEL Health Care
- PSO Consumer Discretionary
- Exchange
- EXEL Nasdaq
- PSO Nasdaq
- Market Cap
- EXEL 9.4B
- PSO 11.2B
- IPO Year
- EXEL 2000
- PSO 2000
- Fundamental
- Price
- EXEL $36.85
- PSO $17.05
- Analyst Decision
- EXEL Buy
- PSO
- Analyst Count
- EXEL 18
- PSO 0
- Target Price
- EXEL $37.24
- PSO N/A
- AVG Volume (30 Days)
- EXEL 2.5M
- PSO 316.1K
- Earning Date
- EXEL 02-11-2025
- PSO 01-01-0001
- Dividend Yield
- EXEL N/A
- PSO 1.72%
- EPS Growth
- EXEL 170.77
- PSO 23.43
- EPS
- EXEL 1.76
- PSO 0.63
- Revenue
- EXEL $2,168,701,000.00
- PSO $4,485,194,688.00
- Revenue This Year
- EXEL $5.36
- PSO N/A
- Revenue Next Year
- EXEL $10.59
- PSO $5.65
- P/E Ratio
- EXEL $20.87
- PSO $25.86
- Revenue Growth
- EXEL 18.49
- PSO N/A
- 52 Week Low
- EXEL $20.14
- PSO $11.78
- 52 Week High
- EXEL $37.59
- PSO $17.25
- Technical
- Relative Strength Index (RSI)
- EXEL 65.59
- PSO 62.25
- Support Level
- EXEL $34.01
- PSO $16.30
- Resistance Level
- EXEL $35.46
- PSO $17.25
- Average True Range (ATR)
- EXEL 1.09
- PSO 0.17
- MACD
- EXEL 0.36
- PSO 0.03
- Stochastic Oscillator
- EXEL 95.70
- PSO 78.95
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About PSO Pearson Plc
U.K.-listed Pearson is the world's largest educational provider. The company has been disposing of noncore businesses such as the Financial Times, The Economist, and publishing house Penguin, and is now focused on being an educational resource and testing provider. While Pearson's primary activity centres on higher-level education, the firm also has significant operations in providing clinical assessments, professional certification and testing.